

BEST AVAILABLE COPY**Docket No.: 1408.017****Substitute Listing of Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

1. **(Currently Amended)** A composition for use in manufacturing an adhesive layer for transdermal preparation, said composition comprising ~~a non-aqueous~~ an organic solvent, a drug to be delivered through skin and an acrylic ~~adhesive polymer~~, and said composition forming one phase, wherein the drug is hydrophilic or in a salt form and the acrylic ~~polymer adhesive~~ has an acrylic backbone and a poly (ethylene oxide) or poly (ethylene oxide) monomethyl ether side chain.
2. **(Previously Presented)** The composition according to claim 1, further comprising at least one additional component chosen from a solubilizer and a skin permeation enhancer.
3. **(Previously Presented)** The composition according to claim 1, wherein the amount of drug in the preparation is in a range of 1-50% by weight, based on the total weight of the adhesive layer.
4. **(Previously Presented)** The composition according to claim 1, wherein the molecular weight of the poly (ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 100-30000, and wherein the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether in the acrylic polymer is in the range of 0.01-50% by weight based on the total weight of the acrylic polymer.
5. **(Previously Presented)** The composition according to claim 4, wherein the molecular weight of the poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 400-5000, and wherein the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether in the acrylic polymer is in a range of 0.05-30 % by weight based on the total weight of the acrylic polymer.

Docket No.: 1408.017

6. **(Previously Presented)** The composition according to claim 1, wherein the drug is selected from a group consisting of sodium, potassium and diethylammonium salts of diclofenac, amfenac, aceclofenac and alclofenac; ketorolac tromethamine; hydrochloride, phosphate and methanesulfonate salts of eperisone and tolperisone; oxybutynin chloride; hydrochloride, hydrobromide, fumarate, succinate and tartrate salts of diphenhydramine, ketotifen, doxylamine, promethazine and trimeprazine; hydrochloride and sulfate salts of tulobuterol, clenbuterol, procaterol and terbutaline; acetate, succinate, valerate and disodium phosphate salts of hydrocortisone, dexamethasone and betamethasone; and hydrochloride salts of ondansetron, granisetron and ramoseiron.

7. **(Previously Presented)** The composition according to claim 2, wherein the solubilizer comprises at least one component selected from a group consisting of ethanol, isopropanol, poly(ethylene glycol), ethoxydiglycol, propylene glycol, glycerin and dimethylsulfoxide, and wherein the amount of solubilizer in the adhesive layer is in a range of 0.5-50% by weight based on the total weight of the adhesive layer.

8. **(Previously Presented)** The composition according to claim 2, wherein the skin permeation enhancer comprises at least one component selected from a group consisting of higher fatty acids; higher alcohols; higher fatty acid esters; fatty acid esters; fatty acid ethers of poly(ethylene glycol); fatty acid esters of poly(ethylene glycol); fatty acid ethers of propylene glycol; fatty acid esters of propylene glycol; sorbitan fatty acid esters; poly(ethylene glycol) sorbitan fatty acid esters; terpenes; sulfoxides; pyrrolidones; amides; and *N*-hydroxy methyl lactate, sorbitol, urea, squalene, olive oil, mineral oil and its derivative, and wherein the amount of skin permeation enhancer in the adhesive layer is in a range of 0.5-50% by weight based on the total weight of the adhesive layer.

9. **(Previously Presented)** The composition according to claim 8, wherein the skin permeation enhancer comprises at least one component selected from a group consisting of lauric acid, oleic acid, lauryl alcohol, oleyl alcohol, glycerol monolaurate, glycerol monooleate, polyoxyethylene(2) lauryl ether, polyoxyethylene(2) oleyl ether, propylene glycol monolaurate,

Docket No.: 1408.017

propylene glycol monooleate, sorbitan monolaurate, sorbitan monooleate, lauryl diethanolamide, *N*-methyl-2-pyrrolidone and isopropyl myristate.

10. *(Previously Presented)* The composition according to claim 7, wherein the amount of the solubilizer and of the skin permeation enhancer in the adhesive layer are each in a range of 1-30% by weight, based on the total weight of the adhesive layer.

11. *(Previously Presented)* The composition according to claim 2, wherein the amount of drug is in a range of 1-50% by weight, based on the total weight of the adhesive layer.

12. *(Previously Presented)* The composition according to claim 2, wherein the molecular weight of the poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 100-30000, and the amount of poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in the range of 0.01-50% by weight based on the total weight of the acrylic polymer.

13. *(Previously Presented)* The composition according to claim 2, wherein the drug is selected from a group consisting of sodium, potassium and diethylammonium salts of diclofenac, amfenac, aceclofenac and alclofenac; ketorolac tromethamine; hydrochloride, phosphate and methanesulfonate salts of oliceridine and tolperisone; oxybutynin chloride; hydrochloride, hydrobromide, fumarate, succinate and tartrate salts of diphenhydramine, ketotifen, doxylamine, promethazine and trimethoprim; hydrochloride and sulfate salts of albuterol, clenbuterol, procaterol and terbutaline; acetate, succinate, valerate and disodium phosphate salts of hydrocortisone, dexamethasone and betamethasone; and hydrochloride salts of ondansetron, granisetron and ramosetron.

14. *(Previously Presented)* The composition according to claim 8, wherein the amount of the solubilizer and of the skin permeation enhancer in the adhesive layer are each in a range of 1-30% by weight, based on the total weight of the adhesive layer.

Docket No.: 1408.017

15. *(Previously Presented)* The composition according to claim 9, wherein the amount of the solubilizer and of the skin permeation enhancer in the adhesive layer are each in a range of 1-30% by weight, based on the total weight of the adhesive layer.

16-17. *(Canceled)*

18. *(Currently Amended)* A method for manufacturing a transdermal preparation, said method comprising
providing an adhesive composition comprising an acrylic adhesive dissolved in an organic solvent and forming one phase, the acrylic adhesive having a poly (ethylene oxide) or poly (ethylene oxide) monomethyl ether side chain;
~~combining a non-aqueous polymer solution with the adhesive composition with a drug to be delivered through skin, wherein the drug is hydrophilic or in a salt form and the non-aqueous polymer solution comprises a polymer having an acrylic backbone and a poly (ethylene oxide) or poly (ethylene oxide) monomethyl ether side chain; and~~
applying the resulting solution to a substrate to form a transdermal preparation having an adhesive layer comprising the drug and the polymer.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.